Tokyo, June 23 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000058198) titled 'Efficacy of Anti-Integrin avb6 Autoantibody for Immune Checkpoint Inhibitor-Induced Colitis' on June 23.
Study Type:
Observational
Primary Sponsor:
Institute - Kobe City Medical Center General Hospital
Condition:
Condition - Immune Checkpoint Inhibitor-Induced Colitis
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - Evaluation of the Utility of Anti-Integrin avb6 Antibodies in Immune Checkpoint Inhibitor-Induced Colitis
Basic objectives2 - Efficacy
Eligibility:
Age-lower limit - 20
years-old
<=
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusio...